[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598315":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Southeast University, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Xuebijing Group",null,"The Xuebijing group consisted of sepsis patients who received both Xuebijing injection and guideline-concordant therapy. Researchers did not provide any additional interventions, but instead observed and documented the clinical outcomes and treatment effects of Xuebijing injection in combination with standard therapy.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Professor Liu Songqiao","CONTACT","+86 25 83262553","liusongqiao@ymail.com",[19],{"facility":20,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"Zhongda hospital, Southeast University","Nanjing","Jiangsu","210009","China","CN",{"type":27,"coordinates":28},"Point",[29,30],118.77778,32.06167,{"lat":30,"lon":29},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Songqiao Liu","Prof","100598315","effect-of-xuebijing-injection-on-outcomes-in-sepsis-patients-under-real-world-conditionsexit-sep-real-100598315",false,"NCT07069894","Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）","Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions: A Patient Registry","EXIT-SEP REAL","Inclusion Criteria:\n\n* Hospitalized patients aged ≥18 years\n* Sepsis diagnosis meeting Sepsis-3 criteria\n* Informed consent signed by patient or legally authorized representative\n\nExclusion Criteria:\n\n* Patients with a prior history of sepsis\n* Sepsis diagnosis \\>48 hours prior to enrollment\n* Current participation in clinical trial","ALL","18 Years",{"count":47,"type":48},5400,"ESTIMATED","28 Days","OBSERVATIONAL","Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.",[53],"Sepsis",[53,55,56],"Xuebijing injection","Intensive Care Unit","NOT_YET_RECRUITING","2025-07-15",{"date":60,"type":61},"2025-07-17","ACTUAL",{"date":63,"type":48},"2025-08-01",{"date":65,"type":48},"2027-09",{"name":5,"class":6},1]